Poster

Universal AAV Enhancer For Improved Viral Titers, Quality, And Reduced Production Costs

Source: Mirus Bio
VirusGEN and RevIT

AAV therapies require high quality and high titers of viral genomes per dosage, prompting the need for a more efficient AAV manufacturing method to reduce overall costs. The RevIT enhancer was created in response to this need with the potential to increase higher genome titers 2-4X in a range of suspension HEK 293 subtypes and cell culture media. Additional features allow you the flexibility to produce multiple AAV serotypes and, when paired with Mirus Bio's TransIT-VirusGen Transfection Reagent, enable complex stability in AAV manufacturing. Explore all the ways RevIT enhances your AAV production.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online